ÂÜÀòÂÒÂ×

Marcos Milla has experience in drug discovery across the areas of autoimmunity and inflammation, neurosciences and pain, and immuno-oncology. His training and expertise encompass the fields of biochemistry, biophysics, molecular pharmacology, cell & molecular biology, and structural biology. He has previously directed efforts focusing on multiple intracellular and extracellular target classes, including cell surface and nuclear receptors, ion channels, kinases and proteinases. He led work on the discovery of break-through series of small molecule modulators of those target classes and of cytokine-receptor (protein-protein) interactions.

Marcos graduated with a BS degree from Universidad Peruana Cayetano Heredia (Lima, Peru) in 1985, and a PhD degree in Cell & Molecular Biology from Saint Louis University in 1990. He did post-doctoral training at MIT as a Jane Coffin Childs Fellow (1990-1993), and at Duke (1993-1995).

He was the Chief Scientific Officer of Synthorx until January of 2020, when Sanofi acquired it; then, he became the Head of Synthorx – A Sanofi Company until January of 2021. Prior to joining Synthorx in the Summer of 2017, he has held industry or faculty appointments at GlaxoSmithKline (1995-1998), the Perelman School of Medicine of the University of Pennsylvania (1998-2005), Roche Palo Alto (2005-2009), Janssen R&D (2009-2106), and Adaptive Biotechnologies (2016-2017). Since 2018, he also holds an Adjunct Faculty appointment at the Skaags School of Pharmacy and Pharmaceutical Sciences of UCSD.